{
    "nctId": "NCT03472508",
    "officialTitle": "A Randomized, Double-Blind, Controlled Trial on the Homocysteine-Lowering Effects of Different Doses of Folic Acid Among Patients With Hypertension According to Methylenetetrahydrofolate Reductase C677T Genotypes",
    "genderBased": true,
    "inclusionCriteria": "for run-in period:\n\n* \uff081\uff09\u2265 45 years old;\n* \uff082\uff09A diagnosis or previous diagnosis of essential hypertension, including anyone currently taking antihypertensive drugs; or for those who have not taken antihypertensive drugs within the last 2 weeks, two consecutive examinations were conducted at least one day apart, and both sitting blood pressure (mean value of 3 measurements) met the following criteria: diastolic blood pressure (DBP) \u226590 mmHg or systolic blood pressure (SBP) \u2265140 mmHg (the second blood pressure was measured at V1);\n* \uff083\uff09If a study participant is a woman of childbearing age, she agrees to use a reliable contraceptive method during the trial;\n* \uff084\uff09Voluntarily participates and has signed an informed consent form.\n\nInclusion Criteria for Double-Blind Treatment Period:\n\n* \uff081\uff09Completed MTHFR C677T gene polymorphism detection in run-in period or MTHFR C677T genotype already known in advance;\n* \uff082\uff09Exhibited good tolerance to enalapril and good overall medication compliance (\\>80%) in run-in period or previously exhibited good tolerance and adherence to ACEI drugs in previous medication history.\n* \uff083\uff09Voluntarily continues to participate in this study.\n* Must have minimum age of 45 Years",
    "exclusionCriteria": "Participants meeting any of the following criteria may not participate in this study:\n\n* \uff081\uff09Women who are pregnant and/or lactating; or women who intend to conceive within a year;\n* \uff082\uff09History of allergies to enalapril, folic acid or other components of the compound drug;\n* \uff083\uff09History of adverse reactions or intolerance to enalapril or other ACE inhibitors, or drugs or supplements containing folic acid;\n* \uff084\uff09Diagnosis or suspicion of secondary hypertension;\n* \uff085\uff09Known serious medical conditions, including: Cardiovascular: patients with clinically diagnosed cardiac dysfunction (NYHA class III and above), hypertrophic obstructive cardiomyopathy, clinically significant valvular heart disease, acute coronary syndrome within the last 3 months, or percutaneous coronary intervention (PCI), or coronary artery bypass graft (CABG); or abnormal pre-enrollment ECG test results with clinically significant arrhythmias (atrial flutter, atrial fibrillation, grade II-III atrioventricular block, etc.); Digestive: a previous diagnosis of various types of viral hepatitis that are still in the active phase; abnormal pre-enrollment liver function test results (ALT, AST, GGT, TBIL, or DBIL 3 times higher than normal, ALB \u2264 30g/L); gastrectomy and/or gastrojejunostomy; gastrointestinal dysfunction; Urinary: pre-enrollment serum creatinine greater than 200\u03bcmol/L; clinical diagnosis of renal artery stenosis, isolated kidney, kidney transplantation and/or other diseases; Endocrine: type 1 diabetes or uncontrolled type 2 diabetes (fasting blood glucose above 11.1 mmol/L at pre-enrollment); previous diagnosis of hyperthyroidism and failure to correct; Respiratory: pulmonary heart disease; chronic obstructive pulmonary disease; Neuropsychiatric: recent transient ischemic attack or stroke (within the last 3 months); peripheral or severe autonomic dysfunction; mental or nervous system dysfunction, inability to express desire; known drug or alcohol dependence; Malignancy, malnutrition, hematopoietic disorders and other serious diseases.\n* \uff086\uff09Significant signs of abnormalities as seen in laboratory tests or physical characteristics, which, at the discretion of the investigators, indicates that the patient is experiencing a serious illness or, may affect the observation and evaluation of the drug's efficacy or adverse events, or renders the patient unsuitable for participating in this study;\n* \uff087\uff09Patients currently taking folate, B12, or B6, or any compounds containing them, who express an inability or a refusal to stop usage;\n* \uff088\uff09Regular usage of folic acid supplements or compounds containing folic acid in the past 3 months;\n* \uff089\uff09Participation in a clinical trial for a drug that has not yet been officially approved for marketing within one month prior to the first visit."
}